

Subject Index

Note: The letters ‘f’ and ‘t’ following locators refer to figures and tables respectively.

A

- Accessory cholera enterotoxin (Ace), 52t, 61–62, 102–106, 176, 228, 259, 264, 268
- Adrenaline, 349
- Africa, *see* Endemic/epidemic cholera in Africa
- Alarmone, 2, 185, 188–190
- Antibiotic resistance, 2, 64, 116, 121–122, 146, 162, 164, 167f, 168, 170–172, 171f, 225, 294, 321
- Antibiotics, 2, 7, 57, 66, 121, 130–131, 161–162, 164, 167–169, 172, 209, 291–292, 298–299, 302, 317, 320, 348
- See also* Antibiotic resistance
- Antigen-presenting cells (APCs), 262–263, 269f
- Antimicrobial resistance, 6, 11–12, 40, 87, 291–305
- See also* Integron-mediated antimicrobial resistance in *V. cholerae*
- Aquatic realm and cholera
- detection of *V. cholerae* from the environments, *see V. cholerae*, detection methods
 - ecology of *V. cholerae*
 - biological factors affecting the organism, 315–322
 - environmental factors affecting the organism, 314–315
 - history of cholera
 - historical background and global occurrence, 312–314
 - old beliefs and myths, 312
 - prediction and prevention of cholera
 - climatological models for prediction, 326–328
 - methods, 328–330
- Ascaris lumbricoides*, 9, 39
- Asia, *see* Asiatic cholera
- Asiatic cholera
- antimicrobial resistance
 - El Tor strains, polymyxin B susceptibility, 11
 - India, reduced susceptibility to ceftriaxone, 12
 - tetracycline resistant strains, 11
 - Thailand, ceftriaxone/quinolones treatment, 12
 - treatment with trimethoprim–sulfamethoxazole, 11
 - cholera in the Indian subcontinent
 - annual incidence of cholera, study, 6–7
 - Bangladesh, mathematical Ogawa–Inaba model study, 7
 - Delhi, incidence of O139 serogroup, 6
 - environmental niches, risk factors, 7
 - Maharashtra, incidence of O139 serogroup, 6
 - Raipur, 6
 - cholera vaccines in Asia
 - biv-WC, and immunogenicity of (Vietnam), 17
 - oral cholera vaccines, efficacy in tsunami victims, 17
 - rCTB-WC, cholera vaccine trials, 17
 - VA1.3, study, 17–18
 - control measures and health-care systems
 - breast-feeding, protection associated, 19
 - case–control studies of cholera risk factors, 19
 - Chinese health-care model, objectives, 18
 - DWTW, impact on cholera, 19
 - use of tube-well water, reduced mortality rates in Bangladesh, 19

- Asiatic cholera (*cont.*)
 molecular epidemiology, 13–16
 the O139 cholera
 “cholera-like diarrhea,” 10
 clinical symptoms, 9–10
 first incidence in Baghdad (1999), 10
 imported cases, 11
 incidence among children, 10
 spread in Asia during 1993–1995, 10f
 other Asian countries, 8–9
 phage typing of *V. cholerae* O1 and O139, 12–13
 phage typing scheme, NICED, 13
 prevention of, traditional medicine and food habits for
 chlorodyne, 18
 herbal formulations, treatment of cholera, 18
 seroepidemiology, 16–17
 vibriocidal antibody titer, study of, 16–17
V. cholerae and parasites, association
 glycoprotein synthesis in rat colon model, 9
 Autoinducers (AIs), 152, 187f, 195–196, 245, 249–250
- B**
Bacillus subtilis genome, 142, 189
 Bacteria, 186
 β -Barrel multimer, 279, 281, 284
 “Bengal,” *see* O139 strains
 Biofilm(s), 2, 7, 69, 107, 109, 131, 146–150, 147f, 152, 152f, 188, 191–197, 193f, 203–204, 207–209, , 234, 249–250, 315, 317–319, 321
 Bis-(3',5')-cyclic-di-guanosine monophosphate (c-di-GMP), 2, 187f, 190–195, 197
- C**
 cAMP, *see* Cyclic adenosine 3',5'-monophosphate (cAMP)
 cAMP receptor protein (CRP), 2, 185–188, 205, 208, 250
 Capsular polysaccharide (CPS), 130–131, 135f, 137–138, 140, 142–143, 153
 c-di-GMP, *see* Bis-(3',5')-cyclic-di-guanosine monophosphate (c-di-GMP)
 cdpA protein, 194
Cep, 62, 102, 105
 cGMP, *see* Cyclic guanosine 3',5'-monophosphate (cGMP)
- Chemotaxis, 2, 107, 204–205, 208–209, 317, 321
 Chinese health-care model, 18
 Chlorodyne, 18
 ‘Cholera cot’ method, 347
 Cholera enterotoxin, 261–263
 immune modulation by, 262–263
 See also Accessory cholera enterotoxin (Ace)
 Cholerae quorum-sensing (Cqs) receptor, 195
 “Cholera-like diarrhea,” 2–3, 10, 60, 224, 233, 265, 303
 Cholera toxin (CT), 1–2, 8–9, 16, 18, 39, 52t, 53, 81, 86, 98, 99f, 100f, 116, 130, 133, 146, 153, 176, 187, 213, 228, 230t, 249, 254, 259, 285, 297, 313, 317, 341–343
 See also Toxins of *V. cholerae*
 Classical strains, 6–7, 9, 11–13, 16, 39, 42, 53–54, 60–61, 85, 101, 103, 106–109, 116–119, 132, 134, 144, 153, 191, 194, 207, 215, 216f, 228–229, 231–232, 266–267, 278, 318–319, 322, 324, 341
 Commonwealth of Independent States (CIS), 51–70
 See also V. cholerae epidemics in Russia/CIS
 Complex class I integrons (*orf513*), 302–303
 beta-lactamases, detection of, 303
 “common region” (ISCR1), 303
 3'-CS, 302–303
 “unique” region, 303
 Complex class 2 integrons, 303
 Copepods, 85, 317, 321, 328–329
 “Core” flagellin, *see* FlaA
 Core oligosaccharide, 132–133, 232
 CpxP protein, 218–219
 CRP, *see* cAMP receptor protein (CRP)
 CT, *see* Cholera toxin (CT)
 CTX Φ , 52t, 53–68, 99, 101–102, 105, 122, 141, 144, 146, 176, 213–214, 216–219, 233f, 249, 313
CtxAB, 101
 CTX Φ^+ non-O1, non-O139 strains, 60–62
 isolated from Uzbekistan, study, 60–61
 infant rabbit model, electron microscopy/PCR analysis, 61–62
 Cyclic adenosine 3',5'-monophosphate (cAMP), 2, 98, 185–188, 187f, 191, 193f, 262–265, 268
 Cyclic guanosine 3',5'-monophosphate (cGMP), 186–187

D

- Deep-well tap water (DWTW), 19
- Dehydration, 37, 53, 65, 79, 161, 341–349, 343t, 347t
- DGC, *see* Diguanylate cyclases (DGC)
- Diguanylate cyclases (DGC), 190–191, 193f, 194, 197, 207
- (S)-4,5-Dihydroxypentane-2,3-dione (DPD), 196
- DWTW, *see* Deep-well tap water (DWTW)

E

- Ecology of *V. cholerae*
 - biological factors affecting the organism, 315–322
 - biofilm formation, 317–318
 - chitinase and chitin utilization, 321–322
 - intracellular existence, 322
 - quorum sensing, 319–321
 - rugose and colonial opacity, 318–319
 - viable but non-culturable state, 315–317
 - environmental factors affecting the organism, 314–315
 - Electrolytes, 161, 260t, 265, 343–344, 349
 - Electrolyte therapy, 161
 - El Niño/Southern Oscillation (ENSO) events, 38, 327
 - El Tor strains, 54–58, 85
 - cholera epidemics in Ukraine/Moldova, 56
 - cholera morbidity in Russian federation (1998–2007), 56f
 - imported cases of cholera in CIS countries, 54f
 - Inaba serotype, resistance to antibiotics, 57
 - isolated in Kazan, PCR analysis, 57
 - strains isolated from Dagestan, 55
 - tested in infant rabbit model, 58
 - VNTR analysis, 54–55
 - waterborne cholera outbreak, 55
- Endemic/epidemic cholera in Africa
 - epidemics and outbreaks, 32–36
 - emergence/reemergence of (2000–2007), WHO reports, 35f
 - high CFR (>5), WHO reports (2000–2007), 34f
 - incidence during 2000–2007, 33t
 - V. parahaemolyticus/Shigella dysenteriae* type 1, pathogens identified, 32–33
 - molecular findings, 42

the organism

- TCP gene/*rtxC* gene, identification of biotypes, 39
 - V. cholerae* O1 Inaba, 39
- risk factors and modes of transmission
 - cholera outbreaks, factors associated, 37–38
 - consumption of leftover foods, risk, 36–37
 - El Niño phenomenon, 38
 - nature of storage vessels of drinking water, role, 36
 - parasite infection and cholera (association), Tanzanian children, 39
 - role of environment and climatic factors, 36
 - water-borne transmission, 36
 - seroepidemiology, 40
 - strategies to curtail cholera outbreaks
 - hygienic practices/methods, reduced risk, *see* Hygienic (preventive) methods
 - use of antimicrobials, 40–42
 - Kenyan/Somalian strains, resistance to chloramphenicol/trimethoprim, 41
 - medicinal plants, antimicrobial properties, 41–42
 - O1 strains isolated, resistance to drugs, 40–41
 - prophylaxis, 41
 - replacement of erythromycin for tetracycline, effects, 41
 - resistance to tetracycline, study, 40
 - Entamoeba histolytica*, 9
 - Evolution of *V. cholerae* as a pathogen
 - emergence of endemic/pandemic *V. cholerae*, 100–101
 - CT⁺, TCP⁺ clone, endemics of, 100–101
 - “de novo” strains, 101
 - evolution of major classes of *V. cholerae*, scheme, 100f
 - pathogenic vs. environmental strains, 100
 - seventh pandemic El Tor O1 clone, 100–101
 - horizontal transfer of *V. cholerae* virulence genes
 - ace* and *zot* genes, discovery of, 102
 - CTXΦ lysogeny control by RS1 phage, 102
 - ORFs in CTXΦ genome, 102

Evolution of *V. cholerae* as a pathogen (*cont.*)

- TCP expression recognition by
 - CTX ϕ , 101
 - pathogenesis of cholera
 - CTX genetic element, 98
 - expression of TCP with CT, 99
 - steps involved, 98
 - virulence factors of *V. cholerae*, 99f
 - reactogenicity of nontoxicogenic vaccines in humans, 103
 - toxins/virulence loci, role
 - hap protease, 106
 - hemolysin, 106
 - motility, 107–108
 - MSHA, 107
 - RTX toxin, 106–107
 - zot* and *ace*, discovery of
 - role as phage morphogenesis proteins, 105
 - zot* activity by CVD101 strain, 103–104
- Exopolysaccharide (EPS), *see* Rugose polysaccharide

F

- Filamentous phages of *V. cholerae* O1 and O139
- att* site-containing region of fs2, 217
 - sequence alignment of CTX ϕ , fs2, and VGJ ϕ phages, 217f
 - development of cholera vaccine, strategies, 217–219
 - ampicillin resistance, wild-type (non-fimbriate)/fimbriate Bgd17, 218–219
 - effect of cpxP on twitching motility, 219f
 - fimbriate phase strain, properties, 218, 219f
 - phase variation in *Salmonella* strains, 217, 218f
 - planktonic vibrios, ideal for, 217–218
 - genomic organization of fs2, 216–217
 - hyperfimbriate strains of *V. cholerae* O1, development, 219–220, 220f
 - isolation from stool samples, 214
 - receptor for filamentous phages fs1 and fs2, 215
 - role in pathogenesis, 215–216
 - effect of filamentous phage infection on fimbriation, 216f
 - as a tool for molecular epidemiology of *V. cholerae*, 214–215
 - amplification of fs2 phage sequence from *V. cholerae* O1 strains, 215f

PCR assays, primers used, 215

typing/subtyping of, 214

FlaA, 147, 206, 317

Flagellar genes, 204–206

FlrA, 205–208

Fs2 phage, 214–216

G

Gene cassette, 3, 293–301, 303–304

Geohelminth parasites, 9

Giardia lamblia, 9

Guanosine 3',5'-bis(diphosphate) [(p)ppGpp], 2, 188–191

H

HAP, 53, 99f, 106

HapR protein, 106, 147, 152, 152f, 188, 191, 193f, 194–197, 195, 248, 250–251, 319, 321–322

Heat-stable enterotoxin (ST), 142, 227, 266

Hemolysin, 1, 3, 61, 103, 106, 153, 227–228, 246, 249, 251, 254, 260t, 265–266, 277–286

See also *Vibrio cholerae*

cytolysin/hemolysin (VCC)

Hemolysin–cytolysin, 265–266

HGT, *see* Horizontal gene transfer (HGT)

HGT, creation of O-antigen diversity, 143–147

DNA sequence determination, genome analysis, 145, 145f

“En bloc” HGT of O-antigen, 144

“En morceaux” or “mosaic” HGT of O-antigen genes, 144

HGT mechanism, evidence for homologous recombination events, 146

V. cholerae strain typing, fingerprint analysis, 144

vehicles for HGT of O-antigen/capsule regions, 146–147

Hikojima, 39, 85, 116, 134

History of cholera

historical background and global occurrence

cholera as a re-emerging disease, 313–314

cholera cases in Bangladesh, 313

clinical/environmental isolates of *V. cholerae*, study, 313

risk factors, 314

seasonal variations in Australia/US, 313

old beliefs and myths

“chole” (bile) and “rein” (to flow), Greek origin, 312

- “miasma” or “bad air,” cause of disease, 312
of people in villages of India/Bangladesh, 312
HlyA gene, 1, 15, 105–107, 178, 266, 278, 285
Horizontal gene transfer (HGT), 1, 129, 133, 143–147, 153, 162, 176, 232
See also HGT, creation of O-antigen diversity
Hygienic (preventive) methods
in-home chlorination, 43
oral cholera vaccine (WC/rbs), case–control study, 43
solar heating of drinking water, 43
use of special containers for water storage, 43
washing hand with soap, 43
Hyperfimbriate strains of *V. cholerae* O1, 219–220, 220f
Hypoglycaemia, 344
Hypovolaemia, 349
- I**
ICEs, *see* Integrating conjugative elements (ICEs)
Inaba, 7, 12, 15–16, 39, 42, 51, 57–58, 81, 85–87, 88f, 116, 134, 136, 215, 216f, 324, 341
Indigofera daleoides, 41
Integrating conjugative elements (ICEs), 1–2, 161–180, 162, 293–295
Integron-mediated antimicrobial resistance in *V. cholerae*
characteristics/classes of integrons, 292–293
capture of gene cassettes by *intI*, 293
integration/excision systems, role in, 293
mobile integrons and superintegrons, 293
class 1 integrons in other vibrios, 303–304
detection in *Vibrio alginolyticus*, 304
detection in *Vibrio fluvialis*, 303–304
detection in *Vibrio parahaemolyticus*, 304
complex class 1 and class 2 integrons in *V. cholerae*, 302–303
epidemiology of *V. cholerae* with class 1 integrons
Africa, 300–301
Europe, 302
South America, 302
South Asia: India, 298–300
South-east Asia, 296–298
mobile integrons (MIs), 293–295
superintegrons (SIs), 295–296
Integrons, 3, 12, 122, 162, 171, 291–305
See also Integron-mediated antimicrobial resistance in *V. cholerae*; Mobile integrons (MIs); Superintegrons (SIs)
International Center for Diarrhoeal Diseases Research Centre, Bangladesh (ICDDR, B), 329
Intracellular small molecule signaling systems in *V. cholerae*, 186–195
cAMP/cGMP, second messengers, 186
cAMP-mediated regulation, 187–188
c-di-GMP, 190–195
c-di-GMP and in vivo gene expression in *V. cholerae*, 192–195
c-di-GMP-mediated signaling in *V. cholerae*, 190–192
DGC and PDE domains, 190
GGDEF and EAL domains, 190
synthesis/degradation, 190
cellular alarmones in *V. cholerae*, 188–190
role of (p)ppGpp, 189–190
stringent response in *E. coli*, 189
stringent response triggered by ppGpp/(p)ppGpp, 189
IS1004 fingerprinting technique, 144, 232
- K**
K-antigen, 130
Killed oral whole-cell cholera vaccine (biv-WC), 17
- L**
Lipid A, 131–132
Lipopolysaccharide (LPS)
core oligosaccharide
biosynthesis, genetics of, 132–133
composition/structure, 132–133
lipid A
biosynthesis, genetics of, 132
composition/structure of, 131–132
O-polysaccharide (O-antigen), 133–143
serogroup O1, 134–137
serogroup O22, 139–141
serogroup O31, 142–143
serogroup O37, 141–142
serogroup O139, 137–139
structural studies, 133
Live cholera vaccine (VA1.3), 17–18

M**Management of cholera**

- cholera stool, characteristics, 343
- cholera toxin, effects, 342–343
- clinical presentations, 343–344
 - assessment of patient for dehydration, 343t
 - hypoglycaemia, 344
 - ‘no dehydration,’ 343
 - ‘some’/‘severe’ dehydration,
 - symptoms, 343–344
 - symptoms in children, 344
- complications, 349
- diagnosis by laboratory examination, 341–342
- epidemics, types, 342
- feeding
 - breastfeeding, 348
 - in children older than 6 months, 348
- history of cholera, phases, 341
- management of vomiting
 - routine use of anti-emetic, impact, 348
 - use of hypo-osmolar ORS, 348
- management with antibiotics, 347–348
 - furazolidone, alternative to tetracycline, 347
 - oral tetracycline, drug of choice, 347
 - quinolones, adult cases, 347
 - selection criteria, 348
- oral rehydration salt (ORS) solution, 345–346
 - composition by weight/osmolarity, 346t
- oral rehydration therapy/intravenous therapy, 344
- other drugs or agents
 - adrenaline and nicotinamide, 349
 - anti-motility drugs, efficacy, 349
 - hypovolaemia, treatment of, 349
 - kaolin and pectin, 348–349
 - zinc and probiotics, 349
- patients with ‘no’ dehydration, 344
- patients with ‘severe’ dehydration, 346–347
 - ‘cholera cot’ method, 347
- intravenous treatment of children/ adults, guidelines for, 346, 347t
- ORS, use in maintenance phase, 347
- treatment with Ringer’s lactate solution, 346
- patients with ‘some’ dehydration, 344–345
- person to person transmission via faecal–oral route, 342

- symptoms, 341
- Vibrio cholerae*, classification, 341
- Mannose-sensitive hemagglutinin (MSHA), 107, 116, 214–215, 318
- Mature biofilm, 148, 150, 209, 317
- MCP, *see* Methyl-accepting chemoreceptors (MCP)
- Methyl-accepting chemoreceptors (MCP), 208
- MLEE/MEE, *see* Multilocus enzyme electrophoresis (MLEE/MEE)
- MLST, *see* Multilocus sequence typing (MLST)
- Mobile integrons (MIs), 293–295
 - class 1 integrons, 293–294, 294f
 - Betaproteobacteria*, source of, 294
 - class 2 integrons, 294
 - class 3 integrons, 294
 - class 5 on plasmid pRVSI of *V. salmonicida* strain, 295
 - SXT^{ET} (class 4), 294–295
- Molecular epidemiology of toxigenic *V. cholerae*
 - characterization of *V. cholerae*
 - CP/TCP, cholera-causative genes, 116
 - H antigen, 115
 - O antigen, 115
 - V. cholerae* O1 strains, biotypes/serotypes of, 116
 - virulence factors, role in cholera pathogenesis, 116
 - epidemiology of cholera, 117
 - influence of clonal diversity on epidemiology of cholera, 123–124
 - molecular basis for clonal diversity, 122–123
 - horizontal transfer of CT genes, mechanism, 122
 - integrons, role in spread of pathogenic genes, 122
 - microarray-based genomic analysis of *V. cholerae* strains, 123
 - molecular epidemiological tools
 - MEE technique, 118
 - MLST method, 118
 - PFGE technique, 118
 - RFLP based genetic typing schemes, 117–118
 - molecular epidemiology of cholera
 - antibiotic resistance among toxigenic *V. cholerae*, 121–122
 - clonal diversity of epidemic strains in Bangladesh/India, 119–121
- Motility of *V. cholerae*, 107–108

- MSHA, *see* Mannose-sensitive hemagglutinin (MSHA)
- Multilocus enzyme electrophoresis (MLEE/MEE), 86, 118, 226, 232
- Multilocus sequence typing (MLST), 118, 144
- N**
- NAG, *see* Non-agglutinable vibrios (NAG)
- NAG-ST, 142, 227, 229
- National Institute of Cholera and Enteric Diseases (NICED), 12–13
- NCV, *see* Non-cholera vibrios (NCV)
- New cholera toxin (NCT), 259, 260t, 267
- NICED, *see* National Institute of Cholera and Enteric Diseases (NICED)
- Nicotinamide, 349
- NMDCY, *see* Non-membrane damaging cytotoxin (NMDCY)
- 'No dehydration,' 343–344
- Non-agglutinable vibrios (NAG), 224
- Non-choleraeragenic strains
- CTX ϕ ⁻/pre-CTX ϕ ⁻ non-O1, non-O139 strains, 66–68
 - CTX ϕ ⁻/pre-CTX ϕ ⁻ O1 strains, 63–66
 - pre-CTX ϕ ⁺ O1 and non-O1, non-O139 strains, 62–63
- Non-cholera vibrios (NCV), 32, 223–234
- See also* Non-O1, non-O139 *V. cholerae*
- Non-membrane damaging cytotoxin (NMDCY), 266
- Non-O1, non-O139 *V. cholerae*
- CTX prophage and VPI, 228–229
 - analysis of VPI genes, 229
 - RFLP analysis, 228
 - tcpA* gene, analysis, 228–229
 - ecology and epidemiology
 - cholera-like outbreaks, reports, 225
 - clinical symptoms, 224
 - extraintestinal infection in man, cause of, 225
 - isolation rates from stool samples, study, 224–225
 - modes of transmission, 225
 - evolutionary perspective, 231–234
 - epidemic-causing *V. cholerae* strains, survival strategies, 234
 - evolution of pathogenic strains of O37/O141 serogroups, model, 233–234, 234f
 - O1/E1 Tor/O139 strains, genomic analysis of, 231–232
 - Sudan/Czechoslovakia strains of O37 serogroup, analysis, 232
 - "non-O group 1 *V. cholerae*", 224
 - pathogenic potential of, 229–231
 - CT produced by non-O1/non-O139 *V. cholerae* strains, mechanisms, 231
 - CT production, colonization efficiency, and lethal toxicity values, 230t
 - RITARD/suckling mouse models, 229
 - strain diversity, 225–226
 - PFGE analysis of *NotI*-digested genomic DNA, 226, 227f
 - toxins and toxigenic factors, 226–228
 - CT/CT-like toxin in non-O group 1 strains, study, 228
 - NAG-ST gene demonstration in Thailand, 227
 - non-O group 1 *V. cholerae* strains isolated from Osaka airport, study, 227
 - virulence factors, 227–228
 - Nontoxicogenic vaccines, reactogenicity of, 103
 - NRT36S strain, 131, 142–143, 145f

O

O-antigen, *see* O-polysaccharide (OPS)

Ogawa, 6–8, 12, 15–16, 39–42, 51, 85–87, 88f, 91, 103, 116, 134, 136, 249, 268, 324, 341

Open reading frames (ORFs), 102, 104, 122, 247

O-polysaccharide (OPS), 130, 133–143

 - serogroup O1, 134–137
 - biotypes/serotypes, 134
 - composition/structure of O1
 - O-antigen, 134
 - O1 O-antigen biosynthesis, genetics of, 134–136, 135f
 - serotype switching in *V. cholerae* O1, 136–137
 - serogroup O22
 - composition/structure of O22
 - O-antigen, 139–140
 - genetics of O22 *wb*^{*} region, 140–141
 - serogroup O31
 - composition/structure of O31
 - O-antigen, 142
 - genetics of O31 *wb*^{*} region, 142–143
 - serogroup O37
 - composition/structure of O37
 - O-antigen, 141
 - genetics of O37 *wb*^{*} region, 141–142
 - serogroup O139
 - composition/structure of O139
 - O-antigen, 137–138

- O-polysaccharide (OPS) (*cont.*)
 discovery of *V. cholerae* O139 Bengal, study, 137
 genetics of O139 *wbf* region, 138–139
- Oral rehydration salt (ORS) solution, 344–348, 346
- Oral rehydration therapy (ORT), 3, 37, 291, 311, 344
- ORFs, *see* Open reading frames (ORFs)
- OrfU*, 52t, 59, 63, 102, 105
- ORT, *see* Oral rehydration therapy (ORT)
- O1 serogroup
 classical strains
 cholera, imported origin/routes of spread, 53
 cholera outbreaks in Russia, 53
 hemagglutinin protease (HAP), role, 53–54
 high-level production of CT/TCP, 53
- El Tor strains, 54–58
 cholera epidemics in Ukraine/
 Moldova, 56
 cholera morbidity in Russian federation (1998–2007), 56f
 imported cases of cholera in CIS countries, 54f
 Inaba serotype, resistance to antibiotics, 57
 isolated in Kazan, PCR analysis, 57
 strains isolated from Dagestan, 55
 tested in infant rabbit model, 58
 VNTR analysis, 54–55
 waterborne cholera outbreak, 55
- O139 strains, 9–11, 58–60
 “cholera-like diarrhea,” 10
 clinical symptoms, 9–10
 first incidence in Baghdad (1999), 10
 hybrid structure of, 130
 imported cases, 11
 incidence among children, 10
 spread in Asia during 1993–1995, 10f
- P**
- PDE, *see* Phosphodiesterases (PDE)
- PFGE, *see* Pulse-field gel electrophoresis (PFGE)
- Phage typing, 12–13, 117
- Phosphodiesterases (PDE), 186, 190–191, 193f, 194, 197
- Planktonic bacteria, 217
- Plasmids, 15–16, 104, 153, 162–163, 168–170, 173–174, 176–177, 180, 214, 219–220, 293, 295, 297–304, 313, 320
- Poisson regression model, 327–328, 328f
- Polysaccharide biosynthesis in *V. cholerae*
 EPS/VPS/rugose polysaccharide, 147–153
 capacity to form biofilms, 148
 EPS/VPS production, 148–149
 regulators of VPS production, 150–152
 rugose, biocides and environmental stresses survival, 148
 type II secretion system in VPS export, 152–153
V. cholerae colonial variants ‘smooth and rugose,’ generation, 147–148
 VPS biosynthesis/analysis of functions of *vps* genes, 149
 VPS cluster, unique to *V. cholerae*, 150
- HGT in creation of O-antigen diversity, 143–147
 mechanism of HGT evidence for homologous recombination events, 146
 vehicles for HGT of O-antigen/capsule regions, 146–147
- inner/outer membrane components in *V. cholerae*, 130
- LPS
 core oligosaccharide, 132–133
 lipid A, 131–132
 O-polysaccharide (O-antigen), 133–143
- Pore-forming toxin (PFT), 52t, 106, 277–286
See also Vibrio cholerae
 cytolysin/hemolysin (VCC)
- Prediction and prevention of cholera
 climatological models for prediction, 326–328
 objective of climate studies, 327
 Poisson regression model, observed vs. predicted case study, 327–328, 328f
 sea surface height and plankton biomass, influence on cholera, 327
 temperature, influence on cholera epidemics, 326–327
 methods for prevention/intervention of cholera, 328–330
 removal of copepods, methods/effects, 329
 simple filtration method, Bangladesh, 330
 zooplankton blooms, influence on *V. cholerae*, 328–329
- Preventive (hygienic) methods
 in-home chlorination, 43
 oral cholera vaccine (WC/rbs), case-control study, 43

- solar heating of drinking water, 43
- use of special containers for water storage, 43
- washing hand with soap, 43
- Proteases produced by *V. cholerae*/other pathogenic vibrios
 - proteases produced by other vibrios
 - V. parahaemolyticus* and others, 252–253
 - V. vulnificus* protease (VVP), 251–252
 - Vibrio cholerae* protease
 - hemagglutinin/protease (HA/P), 246–249
 - other proteases of *V. cholerae*, 251
 - quorum-sensing regulation of HA/P production, 249–250
- Pulse-field gel electrophoresis (PFGE), 13–16, 42, 86–88, 118, 120–121, 225–226, 227f, 232
- Punica granatum*, 41
- Q**
- QSS, *see* Quorum-sensing systems (QSS)
- Quorum sensing, 2, 106, 147, 152, 186, 188, 191, 194–197, 208, 245, 249–250, 252–253, 319–322
 - regulation of HA/P production, 249–250
 - in *V. cholerae* (extracellular), 195–197
 - gene expression and biofilm formation, 196
 - quorum sensing and c-di-GMP, relationship, 197
 - quorum-sensing molecules and pathways, 195–196
- Quorum-sensing systems (QSS), 2, 150, 195, 245, 249–250, 252, 321
- R**
- Randomly amplified polymorphic DNA (RAPD), 42, 226
- Re-emergence of cholera in the Americas
 - environmental aspects of cholera
 - frequency of isolation of *Vibrio* spp., study, 84
 - transmission of cholera, role of fish and shellfish, 83
 - V. cholerae* O1 isolated from water samples in Argentina, 85
 - V. cholerae* O1, survival in aquatic environments, 84
 - epidemiology
 - food as mode of transmission, USA, 82
 - reduced incidence reports, WHO (1999–2001), 83
 - re-emergence in Peru, hypotheses, 81
 - seven pandemics of cholera, 80–81
 - transmission through non-chlorinated water, Mexico, 82
- gastrointestinal infection by *V. cholerae* O1, 79–80
- management of cholera and other related diarrhoeal infections, 85
- molecular characterisation of *V. cholerae* biotypes/serotypes, classification of, 85
- clones of *V. cholerae* O1 biotype El Tor identified, 86
- dendrogram showing genetic diversity, MLEE/UPGMA method, 88–91, 90f
- MLEE study of toxigenic/non-toxigenic O1 strains, 87, 87f
- molecular sub-typing methods, 86
- phenotypic change of Inaba to Ogawa and *vice versa*, 86
- sensitive phenotypic methods, 85–86
- toxigenic/non-toxigenic O1 strains, genetic relationship, 87–88, 88f
- V. cholerae* non-O1 associated with cholera-related diarrhoea, 91–92
- Repeat in Toxin (RTX), 16, 39, 106, 227, 245, 267
- Restriction fragment length polymorphisms (RFLP), 13–14, 86, 117–118, 120, 144, 228
- Rhei rhizoma*, 18
- Ribotyping, 13–16, 42, 56, 86, 117–119, 226
- Risk factors, 7, 19, 36–39, 314
- RTX, *see* Repeat in Toxin (RTX)
- Rugose polysaccharide, 147–153
 - capacity to form biofilms, 148
 - EPS/VPS production, 148–149
 - regulators of VPS production, 150–152
 - rugose, biocides and environmental stresses survival, 148
 - Type II secretion system in VPS export, 152–153
 - V. cholerae* colonial variants ‘smooth and rugose,’ generation, 147–148
 - VPS biosynthesis/analysis of functions of *vps* genes, 149
 - VPS cluster, unique to *V. cholerae*, 150
- Russia, *see* *V. cholerae* epidemics in Russia/CIS
- “Russian O139 strains,” 60

S

- S-CEP, *see* Secreted CHO cell-elongating protein (S-CEP)
- Secreted CHO cell-elongating protein (S-CEP), 267
- Self-transmissible transposon-like element (SXT), 2, 12, 122, 161–180, 294–295
See also SXT/R391 family of ICEs, significance in *V. cholerae*
- Serogroup O1, 134–137
 biotypes/serotypes, 134
 composition/structure of O1 O-antigen, 134
 O1 O-antigen biosynthesis, genetics of, 134–136, 135f
 serotype switching in *V. cholerae* O1, 136–137
- Serogroup O22
 composition/structure of O22 O-antigen, 139–140
 genetics of O22 *wb*^{*} region, 140–141
- Serogroup O31
 composition/structure of O31 O-antigen, 142
 genetics of O31 *wb*^{*} region, 142–143
 glycosyltransferases, 143
 synthesis genes, 143
 translocation and processing genes, 143
- Serogroup O37
 composition/structure of O37 O-antigen, 141
 genetics of O37 *wb*^{*} region, 141–142
- Serogroup O139
 composition/structure of O139 O-antigen, 137–138
 discovery of *V. cholerae* O139 Bengal, study, 137
 genetics of O139 *wbf* region, 138–139
- Seventh pandemic El Tor O1 clone, 100–101
- ‘Severe’ dehydration, 343–344
- Shiga-like toxin, 52t, 260t, 266
- “Shinyaku,” 18
See also Chlorodyne
- Signaling systems (intracellular) in *V. cholerae*, 186–195
 cAMP/cGMP, second messengers, 186
 cAMP-mediated regulation, 187–188
 c-di-GMP, 190–195
 c-di-GMP and in vivo gene expression in *V. cholerae*, 192–195
 c-di-GMP-mediated signaling in *V. cholerae*, 190–192
 DGC and PDE domains, 190
 GGDEF and EAL domains, 190
 synthesis/degradation, 190
 cellular alarmones in *V. cholerae*, 188–190
 role of (p)ppGpp, 189–190
 stringent response in *E. coli*, 189
 stringent response triggered by ppGpp/(p)ppGpp, 189
- Single cell bacteria, 186
- Small molecule signaling systems in *V. cholerae*
 extra- and intracellular small molecule-mediated signaling circuits, 193f
 extracellular quorum sensing, 195–197
 gene expression and biofilm formation, 196–197
 quorum sensing and c-di-GMP, relationship, 197
 quorum-sensing molecules and pathways, 195–196
 intracellular small molecule signaling systems, 186–195
 cAMP/cGMP, second messengers, 186
 cAMP-mediated regulation, 187–188
 c-di-GMP, 190–195
 cellular alarmones in *V. cholerae*, 188–190
 major small molecules in extra- and intracellular signaling, 187f
- ‘Some’ dehydration, 343–344
- Streptococcus mutans* genome, 189
- Superintegrons (SIs), 295–296, 295f
 analysis of gene sequence of *V. cholerae* El Tor N16961
 expression of resistance phenotypes, 295–296
 discovery of resistance cassettes, 296
 and MIs, structural similarity, 295
 vs. MIs, characteristics, 295
- SXT/R391 family of ICEs, significance in *V. cholerae*
 antibiotic resistance, 162
 genetic elements, types, 162
 antibiotic treatment, 162
 conjugative transfer and regulation of conjugative transfer, 173–174
 conjugative transfer entry exclusion, 174–175
 excision and integration, 172–173
 regulation, 175–176
 conserved genes in, 170–171
 dehydration, treatment methods, 161–162

- dissemination of SXT^{MO10}-related ICEs, 164–169
 - in Asia/Africa, 168
 - ICE*PdaSpa1*, 168
 - ICE*VchInd1* and ICE*VchBan1*, 164
 - ICE*VchMex1*, 168
 - ICE*VchSL1*, characterization of, 164
 - life cycle of ICEs, 163f
 - mobilization of *V. cholerae* virulence determinants, 176–179
 - origin of SXT^{MO10}-related ICEs, 169–170
 - SXT^{MO10} discovery in a serogroup of *V. cholerae*, 163–164
 - antibiotic resistance gene cluster in SXT/R391 ICE members, 167f
 - SXT/R391 ICE family members, 165t–166t
 - variable regions in, 171–172
- T**
- Terminalia avicennoides*, 41–42
 - Toxigenic (CTX ϕ^+) *V. cholerae* strains
 - O1 serogroup
 - classical strains, 53–54
 - El Tor strains, 54–58
 - O139 strains, 58–60
 - Toxin-coregulated pilus (TCP), 16, 53, 99, 116, 130, 133, 176, 187, 228, 318
 - Toxins of *V. cholerae*, 260t
 - accessory cholera enterotoxin (Ace), 264
 - cholera enterotoxin, 261–263
 - immune modulation by, 262–263
 - heat-stable enterotoxin (ST), 266
 - hemolysin–cytolysin, 265–266
 - new cholera toxin (NCT), 267
 - NMDCY, 266
 - role in inflammation/immunomodulation in cholera disease, 268–270
 - RTX, 267
 - S-CEP, 267
 - Shiga-like toxin, 266
 - WO7 toxin, 264–265
 - zona occludens toxin (Zot), 264
 - Trichuris trichiura*, 9
 - Type III secretion system (TTSS), 67–68, 227, 233, 233f
- V**
- Variable number of tandem repeat (VNTR), 54–55, 57–58, 60–61, 63–65, 118
 - VCC, *see Vibrio cholerae* cytolysin/hemolysin (VCC)
 - V. cholerae* biofilm formation, 209
 - V. cholerae*, detection methods
 - colony blot lift and hybridization with DNA probes, 323–324
 - conventional bacteriological culture methods, 322–323
 - direct detection by PCR, 324–325
 - commonly used PCR primers, 325t
 - immunological methods, 324
 - V. cholerae* epidemics in Russia/CIS
 - ctxAB*⁻ strains, sporadic cases, 51–52
 - CTX ϕ^+ non-O1, non-O139 strains, 60–62
 - environmental strains, 68–69
 - genetic determinants of *V. cholerae* proteins, 52t
 - non-cholerae strains
 - CTX ϕ^- /pre-CTX ϕ^- non-O1, non-O139 strains, 66–68
 - CTX ϕ^- /pre-CTX ϕ^- O1 strains, 63–66
 - pre-CTX ϕ^+ O1 and non-O1, non-O139 strains, 62–63
 - toxigenic (CTX ϕ^+) *V. cholerae* strains
 - O1 serogroup, 53–58
 - O139 strains, 58–60
 - V. cholerae*, evolution as a pathogen
 - emergence of endemic/pandemic *V. cholerae*, 100–101
 - CT⁺, TCP⁺ clone, endemics of, 100–101
 - “de novo” strains, 101
 - evolution of major classes of *V. cholerae*, scheme, 100f
 - pathogenic vs. environmental strains, 100
 - seventh pandemic El Tor O1 clone, 100–101
 - horizontal transfer of *V. cholerae* virulence genes
 - ace* and *zot* genes, discovery of, 102
 - CTX Φ lysogeny control by RS1 phage, 102
 - ORFs in CTX Φ genome, 102
 - TCP expression recognition by CTX Φ , 101
 - pathogenesis of cholera
 - CTX genetic element, 98
 - expression of TCP with CT, 99
 - steps involved, 98
 - virulence factors of *V. cholerae*, 99f
 - reactogenicity of nontoxigenic vaccine prototypes in humans, 103
 - toxins/virulence loci, role
 - hap protease, 106
 - hemolysin, 106

- V. cholerae*, evolution as a pathogen (*cont.*)
 motility, 107
 MSHA, 107
 RTX toxin, 106–107
zot and *ace*, discovery of
 role as phage morphogenesis
 proteins, 105
zot activity by CVD101 strain, 103–104
- V. cholerae* flagellar synthesis and virulence
 chemotaxis and virulence
 ‘hyperinfectious’ state of human stool
V. cholerae, 209
 MCP, role in flagellar rotation, 208
 suppression of chemotaxis, effects, 208
 electron micrograph showing the sheathed
 polar flagellum, 204f
 flagellar transcription hierarchy
 flagellar genes, expression of, 205
 FlgM secretion, effects, 206
 FlrA/FlrB/FlrC, function of, 206
 four-tiered flagellar transcription
 hierarchy, 204–207, 205f
 structure of flagellum, 204
Vibrio flagellum vs. bacterial
 flagella, 204
 motility and biofilm formation, 209
 motility and virulence
 colonization defects of nonmotile
 mutants, 207
 inverse relation, examples, 207–208
 nonmotile mutants of, study, 203
- V. cholerae*, influence on epidemics
 hemagglutinin/protease (HA/P), pathogenic
 role, 2
 horizontal gene transfer, 1
 ICEs in, 2
 O1/O139, serogroups identified, 1
 signaling pathways, 2
- V. cholerae* non-O1, non-O139
 CTX prophage and VPI, 228–229
 analysis of VPI genes, 229
 RFLP analysis, 228
tcpA gene, analysis, 228–229
 ecology and epidemiology
 cholera-like outbreaks, reports, 225
 clinical symptoms, 224
 extraintestinal infection in man, cause
 of, 225
 isolation rates from stool samples,
 study, 224–225
 modes of transmission, 225
 evolutionary perspective, 231–234
 epidemic-causing *V. cholerae* strains,
 survival strategies, 234
 evolution of pathogenic strains of
 O37/O141 serogroups, model,
 233–234, 234f
 O1/E1 Tor/O139 strains, genomic
 analysis of, 231–232
 Sudan/Czechoslovakia strains of O37
 serogroup, analysis, 232
 “non-O group 1 *V. cholerae*”, 224
 pathogenic potential of, 229–231
 CT produced by non-O1/non-O139
V. cholerae strains, mechanisms, 231
 CT production, colonization efficiency,
 and lethal toxicity values, 230t
 RITARD/suckling mouse models, 229
 strain diversity, 225–226
 PFGE analysis of *NotI*-digested
 genomic DNA, 226, 227f
 toxins and toxigenic factors, 226–228
 CT/CT-like toxin in non-O group 1
 strains, study, 228
 NAG-ST gene demonstration in
 Thailand, 227
 non-O group 1 *V. cholerae* strains
 isolated from Osaka airport,
 study, 227
 virulence factors, 227–228
- V. cholerae* O1, 6–17, 32, 37, 39–42, 54,
 58–59, 61–64, 81–82, 84–87, 91,
 116–123, 132, 136–137, 139–140,
 144, 149–153, 163–164, 165t–166t,
 168–170, 174, 176–180, 194,
 213–220, 223–225, 227f, 228,
 230–234, 249, 264–265, 267–268,
 294, 296–304, 313–315, 317–319,
 321, 323–324, 329, 341, 347
- V. cholerae* O139, 8–14, 17, 39, 58, 87,
 116–117, 119–120, 122, 137,
 139–140, 144, 152–153, 163–164,
 165t, 168–170, 174, 177–178, 177f,
 180, 213–215, 216f, 224, 231, 233,
 294, 298–300, 314, 341
- V. cholerae* O1 Inaba, 39
See also Inaba
- V. cholerae* with class 1 integrons,
 epidemiology
 Africa, 300–301
 Europe, 302
 South America, 302
 South Asia: India, 298–300
 South-east Asia, 296–298

- Viable but non-culturable (VBNC) state, 3, 7, 15, 81, 84–85, 234, 249, 315–318, 323–324
- Vibrio alginolyticus*, 84, 253, 304, 320
- Vibrio cholerae* cytotoxin/hemolysin (VCC)
 El Tor isolates, hemolytic activity, 278
 expression, isolation, and purification, 278–279
 interaction of VCC with nonerythroid cells, 285–286
 mature form of, characteristics, 278–279
 receptor specificity, membrane binding, and bilayer insertion, 283–285
 mechanism of bilayer insertion, 284–285
 structure and biophysical characteristics, 279–283
 crystallographic structure of 79 kDa VCC pro-toxin, 280–281, 280f
 model of pore formation by β -barrel membrane proteins, 279f
 partial unfolding of VCC toxin, induction of, 281, 281f
 transverse urea gradient gel electrophoresis of VCC, effects, 282–283, 282f
 VCC–liposome interaction, 281
- Vibriocidal antibody titer, 16–17
- Vibrio fluvialis*, 166t, 303–304
- Vibrio parahaemolyticus*, 67, 84, 142, 227, 245, 251–253, 304, 315
- Vibrio* pathogenicity island (VPI), 146, 223, 226
- Vibrio* polysaccharide (VPS), *see* Rugose polysaccharide
- Vibrio vulnificus* protease (VVP), 245, 251–254
- VSP islands, 119, 121
- W**
- WO7 toxin, 65, 260t, 264–265, 268
- Z**
- Zona occludens toxin (Zot), 52t, 61–62, 102–107, 232, 259, 260t, 264, 268, 325, 325t
 “Zot receptor,” 104